HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.

Sara S OltraJuan Miguel CejalvoEduardo TormoMarta AlbanellAna FerrerMarta NacherBegoña BermejoCristina HernandoIsabel ChirivellaElisa AlonsoOctavio BurguésMaria Peña-ChiletPilar ErolesAna LluchGloria RibasMaría Teresa Martinez

Published in: Cancers (2020)

In BCVY, we found higher expression of HDAC5. Overexpression of HDAC5 in BCVY correlates with lower survival rates. LMK-235 could be a potential treatment in BCVY.

Keyphrases

poor prognosis
replacement therapy